CymaBay Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis

– NDA is supported by data evaluating seladelpar efficacy and safety in over 500 patients – – Seladelpar is the first New Drug Application from CymaBay in its ongoing mission to help people living with PBC – NEWARK, Calif., Dec. 15, 2023 /PRNewswire/ — CymaBay Therapeutics, Inc. (NASDAQ:…

Click here to view original post

Advertisement — Advertise with Biotech Networks